SARS-CoV-2: a potential novel etiology of fulminant myocarditis

Herz

Volumn 45, Issue 3, 2020, Pages 230-232

  Chen, Chen ^a   Zhou, Yiwu ^a   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR;

ADULT RESPIRATORY DISTRESS SYNDROME; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORONAVIRUS DISEASE 2019; CYTOKINE STORM; DISEASE TRANSMISSION; EVIDENCE BASED MEDICINE; EXTRACORPOREAL OXYGENATION; FULMINANT MYOCARDITIS; HEMODYNAMIC PARAMETERS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LETTER; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY RATE; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PNEUMONIA; POLYMERASE CHAIN REACTION; RESPIRATORY FAILURE; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; WHOLE GENOME SEQUENCING; BETACORONAVIRUS; CHINA; CORONAVIRINAE; CORONAVIRUS INFECTION; PANDEMIC; SARS CORONAVIRUS; VIRUS PNEUMONIA;

BETACORONAVIRUS; CHINA; CORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; MYOCARDITIS; PANDEMICS; PNEUMONIA, VIRAL; SARS VIRUS;

EID: 85081020293     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-020-04909-z     Document Type: Letter

References (27)

1. Su S, Wong G, Shi W et al (2016) Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 24(6):490–502. 10.1016/j.tim.2016.03.003
2. Ksiazek TG, Erdman D, Goldsmith CS et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348(20):1953–1966. 10.1056/NEJMoa030781
3. Zaki AM, van Boheemen S, Bestebroer TM et al (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814–1820. 10.1056/NEJMoa1211721
4. Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet. 10.1016/S0140-6736(20)30185-9
5. Lu R, Zhao X, Li J et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 10.1016/S0140-6736(20)30251-8
6. Zhou P, Yang XL, Wang XG et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 10.1038/s41586-020-2012-7
7. Wu JT, Leung K, Leung GM (2020) Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 10.1016/S0140-6736(20)30260-9
8. Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 10.1016/S0140-6736(20)30211-7
9. Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 10.1016/S0140-6736(20)30183-5
10. Zhu N, Zhang D, Wang W et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 10.1056/NEJMoa2001017
11. Shestakova EA, Motuz LP, Minin AA et al (1991) Some of eukaryotic elongation factor 2 is colocalized with actin microfilament bundles in mouse embryo fibroblasts. Cell Biol Int Rep 15(1):75–84. 10.1016/0309-1651(91)90084-v
12. Rothe C, Schunk M, Sothmann P et al (2020) Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 10.1056/NEJMc2001468
13. Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. 10.1001/jama.2020.1585
14. Cooper LT Jr. (2009) Myocarditis. N Engl J Med 360(15):1526–1538. 10.1056/NEJMra0800028
15. Aretz HT, Billingham ME, Edwards WD et al (1987) Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1(1):3–14
16. Richardson P, McKenna W, Bristow M et al (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93(5):841–842. 10.1161/01.cir.93.5.841
17. Caforio AL, Pankuweit S, Arbustini E et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(33):2636–2648. 10.1093/eurheartj/eht210 (2648a–2648d)
18. Maisch B (2019) Cardio-immunology of myocarditis: focus on immune mechanisms and treatment options. Front Cardiovasc Med 6:48. 10.3389/fcvm.2019.00048
19. Pankuweit S, Moll R, Baandrup U et al (2003) Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol 34(5):497–503. 10.1016/s0046-8177(03)00078-9
20. Kuhl U, Pauschinger M, Noutsias M et al (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111(7):887–893. 10.1161/01.CIR.0000155616.07901.35
21. Ammirati E, Veronese G, Brambatti M et al (2019) Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 74(3):299–311. 10.1016/j.jacc.2019.04.063
22. Li S, Xu S, Li C et al (2019) A life support-based comprehensive treatment regimen dramatically lowers the in-hospital mortality of patients with fulminant myocarditis: a multiple center study. Sci China Life Sci 62(3):369–380. 10.1007/s11427-018-9501-9
23. Wang D, Li S, Jiang J et al (2019) Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. Sci China Life Sci 62(2):187–202. 10.1007/s11427-018-9385-3
24. Tschope C, Cooper LT, Torre-Amione G, Van Linthout S (2019) Management of myocarditis-related cardiomyopathy in adults. Circ Res 124(11):1568–1583. 10.1161/CIRCRESAHA.118.313578
25. Kociol RD, Cooper LT, Fang JC et al (2020) Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation. 10.1161/CIR.0000000000000745
26. Spillmann F, Van Linthout S, Schmidt G et al (2019) Mode-of-action of the PROPELLA concept in fulminant myocarditis. Eur Heart J 40(26):2164–2169. 10.1093/eurheartj/ehz124
27. Tschope C, Van Linthout S, Klein O et al (2019) Mechanical unloading by fulminant myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA concepts. J Cardiovasc Transl Res 12(2):116–123. 10.1007/s12265-018-9820-2